Aarti Pharmalabs LtdQ2 FY23Pharmaceuticals & Biotechnology

Aarti Pharmalabs Ltd

Q2 FY23 Earnings Call Analysis

Management growth scorecard

Revenue

Category 3

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Revenue guidance

Category 3

→Company expects revenue growth of 12%-17% over the next few years, reflecting a solid but moderated pace compared to past CAGR of ~18%-20% (Page 12).
→Growth driven by expansion in three segments: Xanthine, API/intermediates, and CDMO/CMO businesses, with the latter poised for faster growth and higher margins (Pages 11-12).
→CDMO/CMO segment anticipated to grow from ~6% contribution currently to potentially 15%+ in 3 years (Page 11).
→Capacity expansions, including debottlenecking and new Atali project (completed by H2 FY25), will enable volume growth and new product commercializations (Pages 6, 11).
→Despite pressure on Xanthine prices, volume increase and capacity expansion aim to maintain or improve absolute EBITDA (Pages 6, 10).
→New product launches, about 40 developments annually, support sales growth alongside broadening customer base in innovator pharma and food/cosmetics (Pages 3, 13).

Category 3

→Management expects EBITDA growth in FY24 to be around 10%-15%, with sustainable EBITDA margins near 20% ±2%.
→Long-term top-line growth guidance is 12%-17% annually, with PAT growth potentially higher due to manageable debt levels.
→The CDMO/CMO segment is anticipated to grow and contribute over 10% to overall business in FY24, driving margin improvement.
→Capacity expansions, including de-bottlenecking xanthine production and the Atali Greenfield project (completion expected H2 FY25), support growth.
→Revenue growth may moderate due to price corrections in segments like Xanthine, but absolute EBITDA and profits are expected to improve through volume increases and operational efficiencies.
→R&D expenditure remains stable, fueling product filings and innovation, which should contribute to longer-term earnings growth.

Get access to all 5 sections — revenue, margin, fundraise, orderbook, and capex — for Aarti Pharmalabs Ltd and 1,400+ other companies.

→There is no explicit mention of any current or planned new fundraising through debt or equity in the provided transcript.
→The company has indicated ongoing and upcoming capex projects (e.g., Atali project with INR350-500 crores capex) being funded through existing resources and internal accruals.
→Management highlighted reasonable debt levels and focus on EBITDA and PAT growth but did not specify raising new funds.
→The discussions revolve around optimizing existing capacities, backward integration, and capex funded from internal cash flows.
→No direct references to equity issuance or fresh borrowings for expansion were made during the Q&A or management commentary sections.

→Specific current or expected order book or pending orders details were not explicitly stated in the transcript.
→Management highlighted ongoing growth with projects like Atali (expected completion H2 FY25) aimed at capacity expansion.
→Focus is on increasing tonnage and backward integration to meet demand and maintain margins.
→The CMO/CDMO segment is expected to grow significantly, possibly increasing from 6% to 15% contribution over the next three years.
→The company is actively commercializing new products each year, aiming to file around 40 DMFs per year, with 40 filed to date as of FY23.
→Inventories have increased but management expects these to be sold in upcoming quarters, indicating active order fulfillment underway.
→Overall, the company expects stable or growing EBITDA and is optimistic about future order growth tied to capacity expansion and product pipeline.

Yes

→Growth capex of over INR 200 crores incurred in the last couple of years, with INR 130 crores capitalized on the Tarapur project. Ramp-up expected over next 1 to 1.5 years.
→Atali, Gujarat Greenfield project: 80 acres acquired; first phase involves 400k reactor volume capacity, targeting API, intermediates, and CDMO/CMO projects. Completion expected in H2 FY25.
→Additional capacity expansions include debottlenecking Xanthine plant from 4,000 to 5,000 tons per annum, with further debottlenecking planned.
→Maintenance and EHS capex typically INR 50-60 crores per year.
→Future capex plans include potential for 2-3 additional blocks at current API sites based on demand, with flexibility to scale as utilization improves.
→Capital employed for backward integration to reduce imports and improve margins, especially to reduce dependence on China.

How does Aarti Pharmalabs Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Aarti Pharmalabs Ltd

Rev 3Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Aarti Pharmalabs Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.